End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.62 CNY | -0.29% |
|
-3.27% | -16.90% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 64% by 2026.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Revenue estimates are regularly revised downwards for the current and coming years.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.90% | 867M | - | ||
-12.16% | 79.1B | B+ | ||
-3.15% | 7.13B | B- | ||
+21.25% | 3.58B | B- | ||
-9.18% | 2.93B | B- | ||
+16.05% | 1.69B | - | ||
-8.50% | 1.19B | - | ||
-33.05% | 1.11B | B | ||
-36.85% | 1.05B | C- | ||
-27.92% | 939M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300119 Stock
- Ratings Tianjin Ringpu Bio-Technology Co.,Ltd.